Search Clinical Trials
Sponsor Condition of Interest |
---|
The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates
Methodist Health System
Frailty
Sarcopenia
COVID-19
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue
after major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal muscle
mass and strength. It is a key component of physical frailty and is associated with
poorer post-surgical outcomes due to decreased... expand
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality. Type: Observational Start Date: Apr 2022 |
LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized...
Jose David Suarez, MD
COVID-19
The goal of this clinical trial is to learn about the safety and efficacy of Sesderma
LACTYFERRIN™ Forte and Sesderma ZINC Defense™ in non-hospitalized patients with COVID-19.
The main question is:
Is there a reduction in the signs and symptoms of COVID-19 from baseline to end of
treatment? Participants... expand
The goal of this clinical trial is to learn about the safety and efficacy of Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ in non-hospitalized patients with COVID-19. The main question is: Is there a reduction in the signs and symptoms of COVID-19 from baseline to end of treatment? Participants will complete the following activities. - Screening and first day of treatment - Treatment that will be administered for up to 10 days, two treatment evaluation visits will be completed - After treatment completion. Two visits are scheduled, one 28 days after the last dose and the other 60 days after the last dose. Researchers will compare Treatment Group (Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ + Standard of care (SOC)) with the Control group (Placebo +SOC) to see if there is Reduction in the signs and symptoms of COVID-19 at the end of treatment Type: Interventional Start Date: Jun 2023 |
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™...
Abbott Rapid Dx
COVID-19
Influenza A
Influenza Type B
This study is designed as an international prospective, multicentric, clinical study to
investigate the performance and usability of the Panbio™ COVID-19/Flu A&B Rapid Panel
Professional Use and Self- Test devices for the qualitative detection of COVID-19
antigen, Influenza A antigen and Influenza... expand
This study is designed as an international prospective, multicentric, clinical study to investigate the performance and usability of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use and Self- Test devices for the qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in human nasopharyngeal (NP) and mid-turbinate nasal swabs, respectively. This study is part of the performance evaluation to support the CE conformity assessment procedures. Type: Interventional Start Date: Jan 2023 |
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
Abbott Rapid Dx
COVID-19
Influenza A
Influenza Type B
This study is designed as a prospective, multicentric, sample collection study. The
collected samples will be used for diagnostic research, product development and
validation of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of
COVID-19 antigen, Influenza A antigen (H1N1 and... expand
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal and nasopharyngeal swabs by the study sponsor, Abbott. Type: Interventional Start Date: Mar 2022 |
Homeopathic Treatment of Post-acute COVID-19 Syndrome
Southwest College of Naturopathic Medicine
Post-acute Covid-19 Syndrome
To determine whether an individually prescribed homeopathic medicine has an effect
greater than a placebo and is a viable treatment option to improve fatigue and quality of
life for patients suffering from the symptoms of Post-acute COVID-19 Syndrome. The
researchers hope to achieve this goal by conducting... expand
To determine whether an individually prescribed homeopathic medicine has an effect greater than a placebo and is a viable treatment option to improve fatigue and quality of life for patients suffering from the symptoms of Post-acute COVID-19 Syndrome. The researchers hope to achieve this goal by conducting a clinical trial that is scientifically rigorous and clinically relevant. Expected results of this pilot study will be to obtain sufficient experience and preliminary feasibility data to justify a larger clinical trial of this hypothesis. Type: Interventional Start Date: Sep 2021 |
COVID-19 VaccinE Response in Rheumatology Patients
Jeffrey Curtis
Rheumatoid Arthritis
Psoriatic Arthritis
Spondylarthritis
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter
randomized controlled trial designed to evaluate the efficacy and safety of a mRNA
COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and
to evaluate the impact of different immunomodulatory... expand
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment. A primary objective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study. Type: Interventional Start Date: Nov 2021 |
Examine the Psychosocial Impacts of COVID-19 Pandemic.
University of Otago
Psychosocial Impacts
COVID-19 Pandemic
This is an observational study examining the psychosocial impacts of the COVID-19
pandemic in seven low-and-middle income countries (Indonesia, Iran, Iraq, Malaysia,
Pakistan, Somaliland, and Turkiye). The data was obtained on standardised measures of
wellbeing (WHO Well-Being Index), psychological... expand
This is an observational study examining the psychosocial impacts of the COVID-19 pandemic in seven low-and-middle income countries (Indonesia, Iran, Iraq, Malaysia, Pakistan, Somaliland, and Turkiye). The data was obtained on standardised measures of wellbeing (WHO Well-Being Index), psychological distress (Kessler 10), post-traumatic stress (PTSD Checklist for DSM-5), post-traumatic growth (Posttraumatic Growth Inventory), and a novel pandemic-related stress (COVID Psychosocial Impacts Scale). Data was collected employing either a unilingual (in native language) or bilingual online survey (with English as a second language) from participants (N=2574) aged 18 and above using a non-probability convenient sampling. The findings enabled us to examine the psychosocial impacts of COVID-19, validate the translations of the CPIS and standardized measures; and determine the trajectory of study variables with pandemic exposure. Type: Observational Start Date: Dec 2021 |
Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations
University of Oklahoma
Covid19
The pandemic caused by the novel coronavirus SARS-CoV-2 has resulted in substantial
global morbidity and mortality including in Oklahoma and caused unprecedented
interruptions in nearly all aspects of our lives. The population of the state of Oklahoma
is at particular risk to SARS-CoV-2 due to its... expand
The pandemic caused by the novel coronavirus SARS-CoV-2 has resulted in substantial global morbidity and mortality including in Oklahoma and caused unprecedented interruptions in nearly all aspects of our lives. The population of the state of Oklahoma is at particular risk to SARS-CoV-2 due to its large rural population, strained healthcare system, and poor overall health. The Community-Engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations (CATCH-UP) program will involve both practice-based and community-based approaches to maximize the reach of the RADx-UP consortium, broaden the potential perspectives that could be captured, and compare the effectiveness of strategies. The interventions will be pragmatic to allow CATCH-UP to respond to changing attitudes, barriers, and environments as the pandemic progresses as well as expected technology developments to produce more effective viral testing that can provide rapid results to patients. The investigators will assist 50 small primary care practices to implement guidelines-based testing and patient education about COVID-19 and risk mitigation strategies. The project's community-based approach is designed to rapidly respond to community testing needs by deploying mobile testing sites that will provide operational support to increase the efficiency and the existing capacity for state-wide testing by Oklahoma's public health authorities. Together, the investigators estimate that the CATCH-UP program will result in at least 105,000 SARS-CoV-2 tests performed during the first year of implementation. A comprehensive, ongoing evaluation will be performed to analyze patient and provider attitudes, barriers and facilitators of viral testing, identified health disparities caused by COVID-19, effectiveness of the intervention in both settings, and to allow robust collaboration with other RADx-UP consortium sites. Type: Interventional Start Date: Sep 2020 |
Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)
NYU Langone Health
Multiple Sclerosis
Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the
causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic
infection to mild flu-like symptoms to multi system failure and death, resulting in
significant morbidity and mortality worldwide.... expand
Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a novel coronavirus and the causative agent of COVID 19 disease, whose presentation symptoms range from asymptomatic infection to mild flu-like symptoms to multi system failure and death, resulting in significant morbidity and mortality worldwide. Novel vaccines against the SARS-CoV-2 virus have very recently been developed; however, the effectiveness, immune response, and short- or long-term safety of these vaccines have not been tested in immunocompromised patients on anti-CD-20 therapy for multiple sclerosis (MS) or for other disorders. This study will examine the immune response of the Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus given as standard of care (SOC) in MS patients on ocrelizumab. Type: Observational Start Date: Apr 2021 |
Impact of COVID-19 on GU Disease
Icahn School of Medicine at Mount Sinai
COVID-19 Infection
Genitourinary Cancer
Benign Urologic Conditions
The purpose of this research study is to identify patients with GU disease with active or
past COVID-19 infection.
Participants will be asked to:
- Complete an Online COVID-19 Questionnaire.
- Disclose if the patient has or had Genitourinary cancer or benign urologic condition
-... expand
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: - Complete an Online COVID-19 Questionnaire. - Disclose if the patient has or had Genitourinary cancer or benign urologic condition - Provide urine specimen for research - Provide 4 tablespoons of blood for testing blood for research. - Provide permission to access medical records, such as patient lab results, medical history, imaging reports, etc. Type: Observational Start Date: Feb 2021 |
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Inovio Pharmaceuticals
Coronavirus Infection
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19 Disease
This is a Phase 2/3, randomized, placebo-controlled, multi-center trial to evaluate the
safety, immunogenicity and efficacy of INO-4800 administered by intradermal (ID)
injection followed by electroporation (EP) using CELLECTRA® 2000 device to prevent
coronavirus disease 2019 (COVID-19) in participants... expand
This is a Phase 2/3, randomized, placebo-controlled, multi-center trial to evaluate the safety, immunogenicity and efficacy of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device to prevent coronavirus disease 2019 (COVID-19) in participants at high risk of exposure to severe acute respiratory syndrome coronavirus - 2 (SARS-CoV-2). The Phase 2 segment will evaluate immunogenicity and safety in approximately 400 participants at two dose levels across three age groups. Safety and immunogenicity information from the Phase 2 segment will be used to determine the dose level for the Phase 3 efficacy segment of the study involving approximately 7116 participants. Type: Interventional Start Date: Nov 2020 |
Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic
Teachers College, Columbia University
Distress, Emotional
Emotional Dysfunction
Anxiety
Depression
This study is an open trial designed specifically to address the need for evidence-based
treatment delivered via telehealth to individuals that are currently struggling with
mental health issues during the COVID-19 pandemic, with the overarching goal of helping
residents of New York adversely impacted... expand
This study is an open trial designed specifically to address the need for evidence-based treatment delivered via telehealth to individuals that are currently struggling with mental health issues during the COVID-19 pandemic, with the overarching goal of helping residents of New York adversely impacted by the pandemic to effectively manage their anxiety, stress, and depression during this unprecedented time in human history. Type: Interventional Start Date: May 2020 |
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing...
University of Oklahoma
Herpes Zoster
Allergy and Immunology
Corona Virus Infection
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune
system and whether that has any effect on the body's ability to fight off other
infections such as COVID-19. We hypothesize that:
H1: Shingrix vaccination will elevate acute and trained immunity
H2: For... expand
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19. Type: Interventional Start Date: Sep 2020 |
Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia
Ohio State University Comprehensive Cancer Center
Covid-19
Sars-CoV2
Pneumonia
Low doses of radiation in the form of chest x-rays has been in the past to treat people
with pneumonia. This treatment was thought to reduce inflammation and was found to be
effective without side effects. However, it was an expensive treatment and was eventually
replaced with less expensive treatment... expand
Low doses of radiation in the form of chest x-rays has been in the past to treat people with pneumonia. This treatment was thought to reduce inflammation and was found to be effective without side effects. However, it was an expensive treatment and was eventually replaced with less expensive treatment options like penicillin. The COVID-19 virus has emerged recently, causing high rates of pneumonia in people. The authors believe that giving a small dose of radiation to the lungs may reduce inflammation and neutralize the pneumonia caused by COVID-19. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers. The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from COVID-19 infection, which could reduce the need for a ventilator or breathing tube. Type: Interventional Start Date: Aug 2020 |
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19...
Rutgers, The State University of New Jersey
COVID-19
SARS-CoV 2
SARS-CoV Infection
This is an expanded access program providing COVID-19 convalescent plasma to patients
hospitalized with severely or life-threateningly ill COVID-19. expand
This is an expanded access program providing COVID-19 convalescent plasma to patients hospitalized with severely or life-threateningly ill COVID-19. Type: Expanded Access |
Sarilumab for Patients With Moderate COVID-19 Disease
Westyn Branch-Elliman
COVID
Objectives: To determine whether blockade of IL-6R is beneficial in patients with
COVID-19 infection of moderate severity.
Research Design: Randomized, controlled trial. Two-arm trial comparing standard care
alone to standard care with addition of sarilumab (anti-IL6R). The trial will use a
randomized... expand
Objectives: To determine whether blockade of IL-6R is beneficial in patients with COVID-19 infection of moderate severity. Research Design: Randomized, controlled trial. Two-arm trial comparing standard care alone to standard care with addition of sarilumab (anti-IL6R). The trial will use a randomized play-the-winner design, in which randomization becomes weighted toward the arm that was more effective in previous subjects in the trial. Methodology Hospitalized patients meeting clinical criteria for moderate disease and testing positive for coronavirus infection. Interventions: sarilumab, 400 mg subcutaneous injection. Standard care is not pre-specified, may vary among patients, and may include agents with anti-viral activity, such as remdesivir or hydroxychloroquine, among others. Up to 120 patients, primary outcome intubation or death within 14 days. All data will be extracted remotely from the electronic health record (EHR). Clinical Implications: The study has potential to establish IL-6R blockade, delivered subcutaneously, as standard of care in reducing progression to critical illness in patients with moderate COVID-19 disease. Type: Interventional Start Date: Apr 2020 |
COVID-19 Recovered Volunteer Research Participant Pool Registry
University of California, Los Angeles
Recovered From COVID-19
This is a prospective observational registry of COVID-19 recovered patients who are no
longer symptomatic. This Registry is intended to serve as a pool of individuals that can
participate in studies associated with serological testing, characterization of immunity
and immune response, vaccine development,... expand
This is a prospective observational registry of COVID-19 recovered patients who are no longer symptomatic. This Registry is intended to serve as a pool of individuals that can participate in studies associated with serological testing, characterization of immunity and immune response, vaccine development, and convalescent plasma donors. Type: Observational [Patient Registry] Start Date: Apr 2020 |
COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
National Institute of Allergy and Infectious Diseases (NIAID)
Immunodeficiencies
Immune Dysregulations
Background:
The immune system defends the body against disease and infection. Immune deficiencies are
health conditions that decrease the strength of this response. Vaccines stimulate the
immune system to create a defense against a specific type of germ. Researchers want to
compare immune system... expand
Background: The immune system defends the body against disease and infection. Immune deficiencies are health conditions that decrease the strength of this response. Vaccines stimulate the immune system to create a defense against a specific type of germ. Researchers want to compare immune system responses to COVID-19 vaccines in people with and without immune deficiencies. Objective: To learn about how people with immune deficiencies respond to COVID-19 vaccines. Eligibility: People age 3 and older with an immune deficiency who plan to get a COVID-19 vaccine. Healthy volunteers are also needed. Design: Participants will be pre-screened for eligibility, including COVID-19 vaccination history and immune status. Participants will give a blood sample before they get their first COVID-19 vaccine. Blood will be drawn from an arm vein using a needle. Blood can be drawn at the NIH, at a local doctor's office, or at a laboratory. It may also be drawn through a fingerstick at home. Participants will also complete 2 online surveys about their health and COVID-19 history. Additional surveys are optional. Participants will give a second blood sample 2 to 4 weeks after they get the vaccine. They will complete 2 surveys about changes in their health and side effects from the vaccine. If participants get another COVID-19 vaccine dose, they will repeat the blood draw and surveys 3 to 4 weeks later. Participants may give 3 optional blood samples in the 24 months after their last vaccine. They may also give saliva samples every 2 weeks while they are in the study for 6 months following their last vaccine. Participation will last from 1 month to 2 years after the participant's last vaccine. Type: Observational Start Date: Apr 2021 |
Effect of Apollo Wearable on Long COVID-19 Symptoms.
The Board of Medicine
Post-acute Sequelae of SARS-COV-2 Infection
The purpose of this study is to examine how Apollo wearable use impacts symptoms and
quality of life following long COVID. expand
The purpose of this study is to examine how Apollo wearable use impacts symptoms and quality of life following long COVID. Type: Observational Start Date: Oct 2023 |
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the...
Virginia Commonwealth University
Dementia
Since the "National Partnership to Improve Dementia Care" debuted in 2012, almost all
long-stay psychoactive prescribing has been graded by CMS, which has correlated to
decreased use. However, some national data suggest that while these psychoactive
medications are being used less, prescriptions of... expand
Since the "National Partnership to Improve Dementia Care" debuted in 2012, almost all long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased use. However, some national data suggest that while these psychoactive medications are being used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased. Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not mandatorily reported to CMS or graded in a quality-measure. Type: Observational Start Date: Sep 2022 |
Phase 3 Open-Label Controlled Trial of Convalescent Plasma in Early COVID-19 Infection
Larkin Community Hospital
Covid19
The expanded access program for investigational convalescent plasma (CP) is being
utilized nationwide despite its unproven benefit and optimal timing of transfusion. The
optimal administration of CP during a viral pandemic must consider the supply of the
product, ideal patient selection, and appropriate... expand
The expanded access program for investigational convalescent plasma (CP) is being utilized nationwide despite its unproven benefit and optimal timing of transfusion. The optimal administration of CP during a viral pandemic must consider the supply of the product, ideal patient selection, and appropriate timing in order to produce maximum benefit with a scarce resource [2]. Currently, the FDA suggested guidelines for use include "severe", "critical" or at risk for critical disease. The optimal administration of CP with anti-SARS-CoV-2 antibodies is theoretically early in the course of the illness [1], before multiorgan failure or a maladaptive immune response, like seen in the cytokine release syndrome, occurs. Our open-label trial will randomize COVID-19+ patients admitted to the hospital who are at high risk for severe disease to receive 1 dose CP ordered within 48 hours of admission plus standard of care vs. standard of care. The primary clinical endpoint will be time to clinical improvement within 28 days after randomization (based on the ordinal scale as specified below). The purpose of this trial will be to obtain data which can be further utilized in future clinical trials and help clinicians understand the effectiveness of CP. Type: Interventional Start Date: May 2020 |
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
Duke University
Fever After Vaccination
Fever
Seizures Fever
This is a prospective, randomized, open-label clinical trial to evaluate the safety of
COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit
1, as compared to sequential vaccination of COVID-19 vaccine and other vaccines at
separate visits (Visits 1 and 2). expand
This is a prospective, randomized, open-label clinical trial to evaluate the safety of COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential vaccination of COVID-19 vaccine and other vaccines at separate visits (Visits 1 and 2). Type: Interventional Start Date: Oct 2023 |
Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
University of Virginia
COVID-19
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to
assess the safety and efficacy of dupilumab use in hospitalized patients with moderate to
severe COVID-19 infection. Subsequently, we conducted a 1 year follow up study to
investigate the occurrence of Post COVID... expand
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to assess the safety and efficacy of dupilumab use in hospitalized patients with moderate to severe COVID-19 infection. Subsequently, we conducted a 1 year follow up study to investigate the occurrence of Post COVID conditions (PCC) in our study population through assessment of pulmonary function, symptoms, neurocognition and immune biomarkers to observe for any treatment group differences. Type: Interventional Start Date: May 2021 |
Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD)
University of Rochester
Covid19
The purpose of this study is to understand how to prevent COVID-19 spread in a school
like the Mary Cariola Center (MCC) in Rochester, NY by answering questions like these:
how do activities in the school alter chances of infection? Are there people infected
with the COVID-19 virus who have no symptoms?... expand
The purpose of this study is to understand how to prevent COVID-19 spread in a school like the Mary Cariola Center (MCC) in Rochester, NY by answering questions like these: how do activities in the school alter chances of infection? Are there people infected with the COVID-19 virus who have no symptoms? How is spread of COVID-19 affected by vaccination rates? Is there any hesitancy to get the vaccine and what are the reasons? This information will be used to help keep the school open and the students and staff safe. Eligible participants are those that work at the Mary Cariola Center (MCC) and interact with the students at MCC who have a high risk of infection from COVID-19. The study lasts for up to 16 months. Type: Interventional Start Date: May 2021 |
A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection
Larkin Community Hospital
Covid19
This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication
against COVID-19. This encompasses reduction in the number of days to negativization via
nasal swab PCR from the average 14 days and early improvement of symptoms. expand
This study aims to find out the efficacy of Xlear nasal spray as an adjunct medication against COVID-19. This encompasses reduction in the number of days to negativization via nasal swab PCR from the average 14 days and early improvement of symptoms. Type: Interventional Start Date: Aug 2020 |
- Previous
- Next